CME · Insider Trading
CME Group Inc.
Every open-market purchase and sale reported by CME officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Form 4 Filings
50
most recent
Open-Market Buys
1
code P
Sales
7
code S
Reporting Insiders
25
current holders
CME — Recent Form 4 Transactions (latest 2026-09-28)
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-28 | William R Shepard | Director | MIXED | +292 | +$78.63K |
| 2026-09-17 | Sunil Cutinho | Chief Information Officer | MIXED | +1,451 | +$400.10K |
| 2026-09-17 | Julie Winkler | Sr MD Chief Commercial Officer | MIXED | +1,451 | +$400.10K |
| 2026-09-17 | Terrence A Duffy | Chairman and CEO | A | +21,812 | +$6.00M |
| 2026-09-17 | Ken Vroman | Chief Transformation Officer | MIXED | +1,381 | +$380.71K |
| 2026-09-17 | Suzanne Sprague | COO & Global Head of Clearing | MIXED | +1,712 | +$471.76K |
| 2026-09-17 | Derek Sammann | Sr MD Gl Hd Commodities Mkts | MIXED | +1,451 | +$400.10K |
| 2026-09-17 | John Clifford Marchese | Sr MD, General Counsel | MIXED | +543 | +$149.49K |
| 2026-09-17 | Michael G. Dennis | Global Head of Fixed Income | MIXED | +2,044 | +$563.00K |
| 2026-09-17 | Lynne Fitzpatrick | President and CFO | MIXED | +2,748 | +$756.89K |
| 2026-09-17 | Timothy Francis McCourt | Sr MD Global Head Equity & FX | MIXED | +1,258 | +$347.02K |
| 2026-09-17 | Jack J Tobin | MD Chief Accounting Officer | MIXED | +353 | +$97.24K |
| 2026-09-14 | Elizabeth A Cook | Director | Sell | −500 | −$140.06K |
| 2026-09-11 | Terrence A Duffy | Chairman and CEO | Sell | −15,000 | −$4.12M |
| 2026-06-29 | Deborah J Lucas | Director | A | +645 | +$145.12K |
| 2026-06-29 | Dennis Suskind | Director | A | +645 | +$145.12K |
| 2026-06-29 | Martin J Gepsman | Director | A | +645 | +$145.12K |
| 2026-06-29 | Kathryn Benesh | Director | A | +645 | +$145.12K |
| 2026-06-29 | Daniel G Kaye | Director | A | +645 | +$145.12K |
| 2026-06-29 | Rahael Seifu | Director | A | +645 | +$145.12K |
| 2026-06-29 | Robert J Tierney JR | Director | A | +645 | +$145.12K |
| 2026-06-29 | Patrick J Mulchrone | Director | A | +645 | +$145.12K |
| 2026-06-29 | Timothy S. Bitsberger | Director | A | +645 | +$145.12K |
| 2026-06-29 | Bryan T Durkin | Director | A | +645 | +$145.12K |
| 2026-06-29 | Harold Eugene Ford Jr. | Director | A | +1,067 | +$240.07K |
| 2026-06-29 | Patrick W Maloney | Director | A | +645 | +$145.12K |
| 2026-06-29 | Charles P Carey | Director | A | +1,067 | +$240.07K |
| 2026-06-29 | Elizabeth A Cook | Director | A | +645 | +$145.12K |
| 2026-06-29 | William W Hobert | Director | MIXED | +1,067 | +$240.07K |
| 2026-06-29 | Howard J Siegel | Director | A | +1,067 | +$240.07K |
| 2026-06-29 | Phyllis M Lockett | Director | A | +645 | +$145.12K |
| 2026-06-29 | William R Shepard | Director | MIXED | +1,406 | +$318.26K |
| 2026-05-19 | Hilda Harris Piell | Sr MD & Chief HR Officer | Sell | −5,753 | −$1.75M |
| 2026-05-18 | Terrence A Duffy | Chairman and CEO | Sell | −35,000 | −$10.45M |
| 2026-03-30 | William R Shepard | Director | Buy | +1,469 | +$437.10K |
| 2026-03-23 | Jonathan L Marcus | Sr MD General Counsel | Sell | −3,291 | −$1.03M |
| 2026-03-19 | Jonathan L Marcus | Sr MD General Counsel | Sell | −3,291 | −$1.10M |
| 2026-03-17 | Sunil Cutinho | Chief Information Officer | MIXED | +4,598 | +$1.43M |
| 2026-03-17 | Jack J Tobin | MD Chief Accounting Officer | MIXED | +429 | +$133.59K |
| 2026-03-17 | Lynne Fitzpatrick | President and CFO | MIXED | +2,989 | +$930.77K |
| 2026-03-17 | Derek Sammann | Sr MD Gl Hd Commodities Mkts | MIXED | +4,629 | +$1.44M |
| 2026-03-17 | Julie Winkler | Sr MD Chief Commercial Officer | MIXED | +4,598 | +$1.43M |
| 2026-03-17 | Ken Vroman | Chief Transformation Officer | MIXED | +3,941 | +$1.23M |
| 2026-03-17 | Terrence A Duffy | Chairman and CEO | MIXED | +35,036 | +$10.91M |
| 2026-03-17 | Suzanne Sprague | COO & Global Head of Clearing | MIXED | +2,989 | +$930.77K |
| 2026-03-17 | Hilda Harris Piell | Sr MD & Chief HR Officer | MIXED | +4,037 | +$1.26M |
| 2026-03-17 | Jonathan L Marcus | Sr MD General Counsel | MIXED | +2,632 | +$819.60K |
| 2026-03-17 | Timothy Francis McCourt | Sr MD Global Head Equity & FX | MIXED | +2,600 | +$809.64K |
| 2026-03-12 | Ken Vroman | Chief Transformation Officer | Sell | −5,160 | −$1.59M |
| 2026-03-12 | Jack J Tobin | MD Chief Accounting Officer | G | −105 | — |
CME — Current Insider Holders
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| William R Shepard | Director | 264,063 | $77.60M |
| William W Hobert | Director | 127,263 | $37.40M |
| Howard J Siegel | Director | 70,309 | $20.66M |
| Terrence A Duffy | Chairman and CEO | 62,442 | $18.35M |
| Patrick J Mulchrone | Director | 54,130 | $15.91M |
| Bryan T Durkin | Director | 43,652 | $12.83M |
| Larry G Gerdes | Director | 39,651 | $11.65M |
| Julie Winkler | Sr MD Chief Commercial Officer | 32,240 | $9.47M |
| Lynne Fitzpatrick | President and CFO | 28,001 | $8.23M |
| Hilda Harris Piell | Sr MD & Chief HR Officer | 27,702 | $8.14M |
| Jack J Tobin | MD Chief Accounting Officer | 26,109 | $7.67M |
| Sunil Cutinho | Chief Information Officer | 26,077 | $7.66M |
| Martin J Gepsman | Director | 25,644 | $7.54M |
| Elizabeth A Cook | Director | 20,841 | $6.12M |
| Ken Vroman | Chief Transformation Officer | 20,814 | $6.12M |
| Derek Sammann | Sr MD Gl Hd Commodities Mkts | 18,569 | $5.46M |
| Suzanne Sprague | COO & Global Head of Clearing | 15,548 | $4.57M |
| Timothy Francis McCourt | Sr MD Global Head Equity & FX | 14,700 | $4.32M |
| Robert J Tierney JR | Director | 14,345 | $4.22M |
| Timothy S. Bitsberger | Director | 11,766 | $3.46M |
| Michael G. Dennis | Global Head of Fixed Income | 10,997 | $3.23M |
| Charles P Carey | Director | 7,718 | $2.27M |
| Jonathan L Marcus | Sr MD General Counsel | 7,192 | $2.11M |
| Daniel G Kaye | Director | 4,845 | $1.42M |
| Patrick W Maloney | Director | 4,743 | $1.39M |
CME Insider Trading FAQ
Who are the insiders at CME?
25 officers, directors and 10%+ beneficial owners currently report holdings in CME via SEC Form 4.
Are CME insiders buying or selling?
Across the 50 most recent Form 4 filings for CME, 1 were open-market purchases (code P) and 7 were sales (code S). Sales frequently reflect scheduled 10b5-1 plans or tax withholding rather than a view on the stock.
How current is CME insider data?
Form 4 must be filed within two business days of the transaction, so this is close to real time. The most recent CME filing is dated 2026-09-28.
How to read Form 4 activity
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CME quote page; the site-wide leaderboard is on the insider transactions hub.
More on CME
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.